Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)

Andre, F; Hamilton, E; Loi, S; Schmid, P; Yu, TH; Lu, SY; Boston, S; D'Cruz, C; Herbolsheimer, P; Jhaveri, K

CANCER RESEARCH, 2021; 81 (4):

科室
- - 订阅+
  - 更多科室
工具
服务